| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 161 | Method of Continuous Mass Production of Progenitor Stem-like Cells Using a Bioreactor System | US15140578 | 2016-04-28 | US20170067019A1 | 2017-03-09 | Timothy Ray Ho |
| Disclosed herein is a method of culturing cells for cell therapy in a bioreactor. | ||||||
| 162 | Seeding An Adherent Cell Bioreactor With Non-Adherent Cells Increases Seeding Density Limit And Reduces Required Expansion Time | US15306830 | 2015-08-26 | US20170051309A1 | 2017-02-23 | Hanna P. LESCH; Nigel PARKER; Minna KARHINEN; Robert SHAW; Seppo YLA-HERTTUALA; Jonas MALINEN; Eevi LIPPONEN |
| We have found a counter-intuitive way to improve the commercial-scale production of recombinant biological products in adherent-cell bioreactors, which reduces the risk of cell culture contamination, increases total yield and reduces the delay between seeding and harvest, thus minimizing expression product degradation, by inter alia inoculating an adherent culture bioreactor with suspension-adapted producer cells | ||||||
| 163 | METHODS FOR CONTROLLING THE GALACTOSYLATION PROFILE OF RECOMBINANTLY-EXPRESSED PROTEINS | US15345953 | 2016-11-08 | US20170051052A1 | 2017-02-23 | Cornelia Bengea; Lisa M. Rives; Patrick Hossler |
| The present invention relates to methods for modulating the glycosylation profile of recombinantly-expressed proteins. In particular, the present invention relates to methods of controlling the galactosylation profile of recombinantly-expressed proteins by supplementing production medium, e.g., a hydrolysate-based or a chemically defined medium, with manganese and/or D-galactose | ||||||
| 164 | SYSTEM AND METHOD FOR IMPROVED TRANSIENT PROTEIN EXPRESSION IN CHO CELLS | US15209695 | 2016-07-13 | US20170016043A1 | 2017-01-19 | Jonathan ZMUDA; Chao Yan LIU |
| The present invention is directed generally to systems and methods suitable for high level expression of recombinant proteins in suspension CHO cells. In particular, the invention allows introduction of the invention obviates the need to replace, replenish or supplement the growth medium during the procedure. The invention also relates to compositions and kits useful for culturing and transforming/transfecting suspension CHO cells. | ||||||
| 165 | METHOD OF PRODUCING RECOMBINANT HIGH MOLECULAR WEIGHT vWF IN CELL CULTURE | US15201125 | 2016-07-01 | US20170008948A1 | 2017-01-12 | Leopold Grillberger; Manfred Reiter; Wolfgang Mundt |
| Among other aspects, the present invention relates to cell culture conditions for producing high molecular weight vWF, in particular, highly multimericWF with a high specific activity and ADAMTS13 with a high specific activity. The cell culture conditions of the present invention can include, for example, a cell culture medium with an increased copper concentration and/or cell culture supernatant with a low ammonium (NH4+) concentration. The present invention also provides methods for cultivating cells in the cell culture conditions to express high molecular weight vWF and rA13 having high specific activities. | ||||||
| 166 | NOVEL EUKARYOTIC CELLS AND METHODS FOR RECOMBINANTLY EXPRESSING A PRODUCT OF INTEREST | US15104580 | 2014-12-18 | US20170002059A1 | 2017-01-05 | Thomas JOSTOCK; Holger LAUX; Anett RITTER |
| The disclosure pertains to novel eukaryotic cell suitable for recombinant production of a product of interest, wherein the effect of the expression product of an endogenous gene C12orf35 is impaired in said cell, thereby increasing their productivity when recombinantly expressing a polypeptide of interest. Furthermore, the present disclosure provides associated technologies wherein such host cells are used in recombinant production technologies. | ||||||
| 167 | RECOMBINANT FIBRINOGEN HIGH-PRODUCTION LINE AND METHOD FOR PRODUCING SAME | US15108194 | 2014-12-26 | US20160318990A1 | 2016-11-03 | Shusei UNO; Momoko OTAKI; Kouji MURAKAMI; Shoji IDENO |
| The present invention provides a recombinant strain highly producing fibrinogen which is an animal cell strain coexpressing a fibrinogen and an α2PI and/or PAI-2, genes encoding Aα chain, Bβ chain and γ chain of fibrinogen, a production method of a recombinant strain highly producing fibrinogen, including introducing gene(s) encoding α2PI and/or PAI-2 into an animal cell, and coexpressing fibrinogen and α2PI and/or PAI-2 in the animal cell, and a production method of a recombinant fibrinogen including culturing a recombinant strain highly producing fibrinogen in a medium, and recovering fibrinogen from the obtained culture. | ||||||
| 168 | SYSTEMS AND METHODS FOR PRODUCING STEM CELLS DIFFERENTIATED CELLS, AND GENETICALLY EDITED CELLS | US14998228 | 2015-12-24 | US20160222355A1 | 2016-08-04 | Scott Noggle; Daniel John Paul |
| The present invention provides systems and methods for obtaining, generating, culturing, and handling cells, such as stem cells (including induced pluripotent stem cells or iPSCs), differentiated cells, and genetically engineered cells, as well as cells and cell panels produced using such systems and methods, and uses of such cells and cell panels. | ||||||
| 169 | METHODS FOR CONTROLLING THE GALACTOSYLATION PROFILE OF RECOMBINANTLY-EXPRESSED PROTEINS | US15086739 | 2016-03-31 | US20160207992A1 | 2016-07-21 | Cornelia Bengea; Lisa M. Rives; Patrick Hossler |
| The present invention relates to methods for modulating the glycosylation profile of recombinantly-expressed proteins. In particular, the present invention relates to methods of controlling the galactosylation profile of recombinantly-expressed proteins by supplementing production medium, e.g., a hydrolysate-based or a chemically defined medium, with manganese and/or D-galactose | ||||||
| 170 | METHOD FOR PRODUCING MEGAKARYOCYTES, PLATELETS AND/OR THROMBOPOIETIN USING MESENCHYMAL CELLS | US14899828 | 2014-06-27 | US20160177265A1 | 2016-06-23 | Yumiko Matsubara; Takeru Zama; Yasuo Ikeda; Yukako Uruga; Toshio Suda; Sahoko Matsuoka |
| Provided is a megakaryocyte and/or platelet production method, enabling to produce a megakaryocyte and/or platelet from mesenchymal cells such as preadipocytes in a relatively short period of time, simply, in a large amount and at lower cost or more efficiently in vitro and a method for producing TPO simply and in a larger amount. A first invention is a method for producing a megakaryocyte and/or platelet, comprising culturing a mesenchymal cell in a mesenchymal cell culturing basic medium containing an iron ion and an iron transporter and collecting megakaryocytes and/or platelets from a culture. A second invention is a method for producing thrombopoietin, comprising culturing a mesenchymal cell or mesenchymal cell-derived megakaryocyte in a mesenchymal cell culturing basic medium containing an iron ion and an iron transporter and collecting thrombopoietin from a culture. A third invention is a method for producing thrombopoietin, comprising culturing a preadipocyte in a preadipocyte culturing basic medium containing dexamethasone, 3-isobutyl-1-methylxanthine and insulin and collecting thrombopoietin from a culture. | ||||||
| 171 | METHODS FOR CONTROLLING THE GALACTOSYLATION PROFILE OF RECOMBINANTLY-EXPRESSED PROTEINS | US15014694 | 2016-02-03 | US20160152702A1 | 2016-06-02 | Cornelia Bengea; Lisa M. Rives; Patrick Hossler |
| The present invention relates to methods for modulating the glycosylation profile of recombinantly-expressed proteins. In particular, the present invention relates to methods of controlling the galactosylation profile of recombinantly-expressed proteins by supplementing production medium, e.g., a hydrolysate-based or a chemically defined medium, with manganese and/or D-galactose | ||||||
| 172 | DAC HYP compositions and methods | US14671653 | 2015-03-27 | US09340619B2 | 2016-05-17 | Taymar E. Hartman; Paul W. Sauer; John E. Burky; Mark C. Wesson; Ping Y. Huang; Thomas J. Robinson; Braeden D. Partridge; J. Yun Tso |
| The present disclosure relates to compositions of daclizumab suitable for subcutaneous administration and methods of manufacturing thereof. | ||||||
| 173 | DAC HYP compositions and methods | US14735062 | 2015-06-09 | US09260528B2 | 2016-02-16 | Taymar E. Hartman; Paul W. Sauer; John E. Burky; Mark C. Wesson; Ping Y. Huang; Thomas J. Robinson; Braeden D. Partridge; J. Yun Tso |
| The present disclosure relates to compositions of daclizumab suitable for subcutaneous administration and methods of manufacturing thereof. | ||||||
| 174 | Methods for controlling the galactosylation profile of recombinantly-expressed proteins | US14619799 | 2015-02-11 | US09255143B2 | 2016-02-09 | Cornelia Bengea; Lisa M. Rives; Patrick Hossler |
| The present invention relates to methods for modulating the glycosylation profile of recombinantly-expressed proteins. In particular, the present invention relates to methods of controlling the galactosylation profile of recombinantly-expressed proteins by supplementing production medium, e.g., a hydrolysate-based or a chemically defined medium, with manganese and/or D-galactose. | ||||||
| 175 | METHODS OF UPSCALING MESENCHYMAL STROMAL CELL PRODUCTION, COMPOSITIONS AND KIT THEREOF | US14597135 | 2015-01-14 | US20160002601A1 | 2016-01-07 | Udaykumar Kokundkar; Swathi Sundar Raj; Sudha Balasubramanian; Charan Thej; Ashwin Kunigal Mruthynjaya; Devi Damodaran; Balamurugan Ramadasse; Anish Sen Majumdar; Swaroop Bhagwat |
| The present invention discloses a method of isolation, pooling and further culturing of Mesenchymal Stem cells (MSC) for clinical application. Present invention also discloses the method of establishing Master Cell bank, followed by Working Cell Bank from which the final therapeutic composition referred to as Investigational Product/Investigational Medicinal Product comprising of allogenic bone marrow-derived MSC is formulated for clinical applications. Present disclosure also discloses a robust manufacturing process for consistent production of clinical grade Mesenchymal Stromal cells (MSCs). The process enables production of highly viable potent cells. The process steps relating to preparation of media, cell seeding, harvesting are fine tuned to achieve consistency in cell yield, superior cell viability, purity, improved cell proliferation, high cell recovery, low HLA-DR expression, reduction in culture duration. The viability and purity of cells are further improved by optimized wash process without cell loss/cell stress. The disclosure further provides a method of cyrostoring MSCs at high cell density without affecting the viability of cells. It further provides economical means to store and transport at −80° C. | ||||||
| 176 | DAC HYP COMPOSITIONS AND METHODS | US14735062 | 2015-06-09 | US20150274832A1 | 2015-10-01 | Taymar E. HARTMAN; Paul W. Sauer; John E. Burky; Mark C. Wesson; Ping Y. Huang; Thomas J. Robinson; Braeden D. Partridge; J. Yun Tso |
| The present disclosure relates to compositions of daclizumab suitable for subcutaneous administration and methods of manufacturing thereof. | ||||||
| 177 | Fed batch method of making anti-TNF-alpha antibodies | US14563993 | 2014-12-08 | US09073988B2 | 2015-07-07 | Itzcoatl A. Pla; Joseph G. Matuck; John C. Fann; Christof Schulz; Nichole A. Roy; David F. Bruton; James McIntire; Yu-hsiang D. Chang; Thomas Seewoester |
| The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture. | ||||||
| 178 | Chinese hamster ovary cell line | US13822371 | 2011-09-14 | US09068198B2 | 2015-06-30 | Diane Hatton; Ray Field; Wyn Forrest-Owen; Victoria Richardson |
| The present invention is related to a Chinese hamster ovary cell line as deposited with the European Collection of Cell Cultures (ECACC) under accession number 10090201; use of the cell line for the production of a recombinant polypeptide; a kit comprising the cell line; and methods for the production of recombinant polypeptide. | ||||||
| 179 | CELL CULTURE IMPROVEMENTS | US14294821 | 2014-06-03 | US20150125905A1 | 2015-05-07 | Itzcoatl A. Pla; Joseph G. Matuck; John C. Fann; Christof Schulz; Nicole A. Roy; David F. Bruton; James McIntire; Yu-Hsiang David Chang; Thomas Seewoester |
| The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture. | ||||||
| 180 | HIGH-CONCENTRATION STEM CELL PRODUCTION METHOD | US14405320 | 2013-05-23 | US20150118748A1 | 2015-04-30 | Jeong Chan Ra; Sung Keun Kang; Jung Youn Jo |
| The present invention relates to a method for preparing stem cells in high concentration. The present invention makes it possible to grow stem cells in an amount sufficient to be clinically usable in a short time, and makes it possible to relatively efficiently enhance the ability of administered stem cells to efficaciously reach target tissue and exhibit an action in a stable fashion and can therefore dramatically increase the efficacy of cell therapy using stem cells. | ||||||
QQ群二维码
意见反馈
意见反馈